International conference

Chennai: Confederation of Indian Industry (CII) in association with Indian Space Research Organization (ISRO), NewSpace India Limited (NSIL) and Antrix Corporation Ltd will host international space conference and exhibition from September 13 to October 4 2021.

The theme of the digital conference and exhibition will be “Building a New Space in India” with the aim of facilitating and strengthening industry participation in the manufacture of satellites, launchers and the use of space applications in various sectors, CII said.

The conference would include digital interactions and a virtual exhibition and will also highlight initiatives taken by the Indian government (establishment of the sectoral regulator Indian National Space Promotion and Authorization Center-INSPACe) and the Indian space agency ISRO to encourage and engage national industry in the sector space and presenting opportunities for Indian industry.

According to CII, the global space economy is valued at $ 385 billion in 2020 and is expected to reach $ 428 billion by 2028, according to the findings of consultancy firm EuroConsult.

This growth is made possible by growing demand for space services, lower costs, miniaturization and access to technology, liberal funding and enabling regulations around the world.

India, which currently holds a 2% share of global space trade, holds great promise as a destination for increasing space trade and also as a manufacturing hub.

Participation in City events is subject to our terms and conditions.

LOS ALAMITOS, Calif., June 24, 2021 – The IEEE International Conference on Quantum Computing and Engineering (QCE21), a multidisciplinary event that bridges the gap between the science of quantum computing and the development of a industry that surrounds it, reveals its full lineup. Taking place virtually from October 18-22, 2021, QCE21 will offer a series of world-class presentations, as well as workforce building tutorials, community building workshops, technical document presentations, stimulating panels and innovative posters. Register here.

Also known as IEEE Quantum Week, QCE21 is unique in incorporating academic and business conference dimensions and will reveal cutting-edge research and developments in quantum research, practice, applications, education and training.

QCE21 keynote speakers include the following pioneers and quantum leaders:

Alan Baratz – D-Wave Systems, President and CEO
James S. Clarke – Intel Labs, Director of Quantum Hardware
David J. Dean – Oak Ridge National Laboratory, Director of the Quantum Science Center
Jay Gambetta – IBM Quantum, IBM Fellow & VP Quantum Computing
Sonika Johri – IonQ, Senior Scientist in Quantum Applications
Anthony Megrant – Google Quantum AI, Principal Investigator
Prineha Narang – Harvard University and Aliro Quantum, professor and technical director
Brian Neyenhuis – Honeywell Quantum Solutions, Head of Business Operations
Urbasi Sinha – Raman Research Institute, Bangalore, professor
Krista Svore – Microsoft, Managing Director of Quantum Systems

Through the participation of the international quantum community, QCE21 has developed an extensive conference program with world-class speakers, technical document presentations, innovative posters, exciting exhibitions, technical briefings, hand strengthening tutorials -work, community building workshops, stimulating panels and birds. Plume sessions.

Papers accepted by QCE21 will be submitted to the IEEE Xplore Digital Library and the best papers will be invited to the IEEE Transactions on Quantum Engineering (TQE) and ACM Transactions on Quantum Computing (TQC) journals.

QCE21 is co-sponsored by IEEE Computer Society, IEEE Communications Society, IEEE Council of Superconductivity, IEEE Future Directions Committee, IEEE Photonics Society, IEEE Technology and Engineering Management Society, IEEE Electronics Packaging Society, IEEE Signal Processing Society (SP) and IEEE Society of Devices electronic (EDS).

The first quantum week of IEEE 2020 laid a solid foundation and was a great success – more than 800 people from 45 countries and 225 companies attended the first event which offered over 270 hours of programming on computing and quantum engineering.

The second annual Quantum Week 2021 will virtually connect a wide range of leading quantum professionals, researchers, educators, entrepreneurs, champions and enthusiasts to exchange and share their experiences, challenges, research results, innovations, applications and enthusiasm, on all aspects of the world. quantum computing, engineering and technologies. The IEEE Quantum Week program will take place during Mountain Daylight Time (MDT).

Visit IEEE QCE21 for all event news, including sponsorship and exhibitor opportunities.

The QCE21 registration package provides virtual access to the IEEE Quantum Week October 18-22, 2021 as well as on-demand access to all events registered through December 2021 with over 270 hours of programming in the field of quantum computing and engineering.

About the IEEE Computer Society

The IEEE Computer Society is the global home of computing, engineering, and technology. A global leader in access to computer science research, analysis and information, the IEEE Computer Society offers a comprehensive range of unmatched products, services and opportunities for individuals at all stages of their life. professional career. Known as the premier organization that empowers people who drive technology, the IEEE Computer Society offers international conferences, peer-reviewed publications, a unique digital library, and training programs.

---

Source: IEEE

Lyon, France–(COMMERCIAL THREAD) – Regulatory news:

ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative protein and peptide formulations, today announced an oral presentation on the M1Pram (ADO09) bi-hormonal treatment at the 14th International Conference on Advances in Diabetes Technologies and Treatments (ATTD 2021), to be held from June 2 to 5, 2021 as a virtual event.

Below is detailed information about the presentation:

About ATTD

ATTD, a scientific program that brings together renowned international experts to discuss major advances in diabetes treatments, technological innovations and present the latest developments in insulin analogues, delivery systems, pumps, glucose sensors, closed loop systems, etc.

About Adocia

Adocia is a clinical-stage biotechnology company specializing in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In diabetes, Adocia’s portfolio of injectable therapies is among the largest and most differentiated in the industry, with five clinical stage products and several preclinical products. The proprietary BioChaperone^® technology platform is designed to improve the efficacy and / or safety of therapeutic proteins while facilitating their use by patients. Adocia personalizes BioChaperone to each protein for a given application.

Adocia’s clinical pipeline includes four new formulations of insulin for the prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone^® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone^® Combo) and a combination of a mealtime insulin with an amylin analogue pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone^® glucagon) for the treatment of hypoglycemia.

Adocia’s preclinical pipeline includes bihormonal combinations for the treatment of diabetes: two combinations of fast-acting insulin analogues and Pramlintide (BioChaperone^® Lispro and BioChaperone stroller^® Aspart Pram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone^® Glargine Liraglutide). In addition, there are two bi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone^® Glucagon Exenatide) and a combination of pramlintide and exenatide (PramExe).

Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on the development of a hydrogel scaffold for people with type 1 diabetes. The first patent application supporting this program has been filed.

Warning

This press release contains certain forward-looking statements regarding Adocia and its business. These forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in these forward-looking statements will be verified, which estimates are subject to numerous risks, including the risks set out in the “Risk factors” section of the Universal Registration Document filed with the Authority. French. financial markets on April 20, 2021 (a copy of which is available at www.adocia.com) and changes in economic conditions in the financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or currently considered to be immaterial by Adocia. The occurrence of some or all of these risks could cause the actual results, financial conditions, performance or achievements of Adocia to differ materially from these forward-looking statements. This press release and the information it contains do not constitute an offer to sell or the solicitation of an offer to purchase Adocia shares in any jurisdiction.